Kotinos Pharmaceuticals, Inc.
http://
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kotinos Pharmaceuticals, Inc.
Beckley Psytech Takes Another Step Toward Psychedelic Antidepressants
The private British biotech announced positive results from its Phase IIa study of BPL-003, which it said support its Phase IIb study of the same DMT-based drug.
BD Moves The Needle To High-Growth Segments
Becton Dickinson is investing in high-growth segments and is on a mission to simplify its business. CEO Tom Polen’s 2025 strategy targets 25% operating margin from both innovations and durable core business combined, as senior BD executives told In Vivo during a break at J.P. Morgan 2024.
BD Moves The Needle To High Growth Segments
Becton Dickinson is investing in high-growth segments and is on a mission to simplify its business. CEO Tom Polen’s 2025 strategy targets 25% operating margin from both innovations and durable core business combined, as senior BD executives told In Vivo during a break at J.P. Morgan 2024.
The Lights Are Going Out At Lumira, But Roche Is Stepping In
The struggling diagnostics company, initially valued at $5bn, has agreed to be purchased by Roche for a comparatively paltry $295m.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Zein Biotec PLC
- ZEINCRO S.A.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice